Cutera (NASDAQ:CUTR) Coverage Initiated by Analysts at StockNews.com

Research analysts at StockNews.com started coverage on shares of Cutera (NASDAQ:CUTR) in a report released on Wednesday. The firm set a “sell” rating on the medical device company’s stock.

CUTR has been the topic of several other research reports. Stephens dropped their target price on Cutera from $10.00 to $5.00 and set an “overweight” rating on the stock in a research report on Friday, August 9th. Piper Sandler reiterated a “neutral” rating and set a $1.00 price objective (down from $3.00) on shares of Cutera in a research note on Friday, August 9th.

Cutera Stock Down 6.4 %

NASDAQ CUTR opened at $0.41 on Wednesday. The firm has a market cap of $8.27 million, a P/E ratio of -0.06 and a beta of 1.26. The company’s 50 day moving average is $0.57 and its 200-day moving average is $1.06. Cutera has a 12-month low of $0.28 and a 12-month high of $4.97.

Institutional Trading of Cutera

Several institutional investors and hedge funds have recently bought and sold shares of CUTR. Ground Swell Capital LLC purchased a new position in shares of Cutera during the 2nd quarter valued at $37,000. Bank of Montreal Can boosted its stake in Cutera by 14.2% during the second quarter. Bank of Montreal Can now owns 282,704 shares of the medical device company’s stock valued at $455,000 after buying an additional 35,248 shares during the period. Finally, Squarepoint Ops LLC grew its position in Cutera by 164.5% during the second quarter. Squarepoint Ops LLC now owns 113,964 shares of the medical device company’s stock worth $172,000 after buying an additional 70,870 shares in the last quarter. 90.70% of the stock is currently owned by hedge funds and other institutional investors.

About Cutera

Cutera, Inc provides aesthetic and dermatology solutions for medical practitioners worldwide. It develops, manufactures, and markets energy-based product platforms for medical practitioners; and distributes third-party manufactured skincare products. The company provides AviClear for the treatment of mild, moderate, and severe inflammatory acne vulgaris; Secret PRO, a device that utilizes fractional CO2 for skin resurfacing and radio frequency (RF) microneedling for skin revitalization; truFlex, a bio-electrical muscle stimulation device designs to strengthen, firm and tone the abdomen, buttocks, and thighs; and excel V/V+, a vascular and benign pigmented lesion treatment platform.